<DOC>
	<DOCNO>NCT02596048</DOCNO>
	<brief_summary>This Phase IV multicenter , open-label study implement order ass diagnostic image quality MDCTA subject undergoing computed tomography angiography ( CTA ) thoraco-abdominal aorta , carotid , pulmonary peripheral artery IOMERON .</brief_summary>
	<brief_title>A Multicenter Study Iomeron®-400 Used With Multi-detector Computed Tomography Angiography ( MDCTA )</brief_title>
	<detailed_description>This Phase IV multicenter , open-label study implement order ass diagnostic image quality MDCTA subject undergoing computed tomography angiography ( CTA ) thoraco-abdominal aorta , carotid , pulmonary peripheral artery IOMERON . The hypothesis IOMERON use high concentration provide good diagnostic image quality . The Investigators also function reader evaluate image on-site . Efficacy analysis base on-site evaluation . Imaging condition representative use routine clinical practice . The study conduct approximately 10-20 site China . Each site may enroll approximately 40 subject study . Approximately 400 subject enrol order obtain 360 evaluable subject undergo elective MDCTA thoraco-abdominal aorta , carotid , pulmonary peripheral artery .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Aortic Diseases</mesh_term>
	<criteria>1 . Provides write Informed Consent willing comply protocol requirement 2 . Is least 18 year age . 3 . Is schedule undergo elective thoracoabdominal aorta , carotid , pulmonary peripheral MDCTA examination . 1 . Is pregnant lactate female . Exclude possibility pregnancy : test site institution ( serum urine βHCG ) within 24 hour prior start investigational product administration , surgical history ( e.g. , tubal ligation hysterectomy ) , postmenopausal minimum 1 year without menses ; 2 . Has know allergy one ingredient IOMERON history hypersensitivity iodinate contrast agent ; 3 . Has moderate severe renal impairment ; 4 . Has receive investigational compound and/or medical device within 30 day admission study ; 5 . Has enrol previously study 6 . Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or postdose followup examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>